The tirzepatide pen peptide: how Mounjaro's KwikPen works and what to expect

Tirzepatide is the UK's only dual GIP and GLP-1 receptor agonist licensed for weight management, delivered via a pre-filled KwikPen injected once weekly.
Each pen contains four doses across four weeks; treatment starts at 2.5 mg and is titrated by your prescriber in steps up to 15 mg.
The two peptide pathways it activates (GIP and GLP-1) work together to reduce appetite, slow stomach emptying and support blood-sugar regulation.
Injection sites are the abdomen, thigh or upper arm; rotating the site each week reduces local skin reactions.

Tirzepatide — sold in the UK as Mounjaro — is a dual peptide medicine delivered via a pre-filled KwikPen, injected once a week. Each pen contains four doses. It works by mimicking two gut hormones, GIP and GLP-1, to reduce appetite and slow gastric emptying. As a prescription-only medicine, a prescriber must assess your suitability before treatment begins. If you've been reading about the tirzepatide peptide pen and aren't sure how it actually works in practice, you're in the right place. Most people come to this question with a mix of curiosity and slight apprehension, wondering whether a weekly injection is as straightforward as it sounds. It is, and this page explains exactly why.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Using the tirzepatide peptide pen in practice: a step-by-step sequence

Step 1, Understanding what the pen contains and why it's a peptide medicine

The word "peptide" describes the class of molecule tirzepatide belongs to. Peptides are short chains of amino acids that mimic or interact with proteins in the body; tirzepatide is a synthetic peptide engineered to bind to both the GIP receptor and the GLP-1 receptor simultaneously. That dual action is what makes it distinct from semaglutide, which targets only the GLP-1 pathway.

In practical terms, this means the Mounjaro KwikPen is delivering a molecule that speaks to two appetite-regulating systems at once. GIP and GLP-1 are both released naturally after eating; tirzepatide amplifies those signals, helping you feel full sooner and for longer, while also slowing the rate at which food leaves the stomach. The result, documented in SURMOUNT-1, published in the New England Journal of Medicine, was an average body-weight reduction of around 20–21% at the 15 mg dose over 72 weeks in adults with obesity.

If you want to understand the device before you begin, our guide to tirzepatide pens and how they work covers the pen's physical format in more depth. You take it out of the fridge, let it reach room temperature as directed in the Patient Information Leaflet, attach a needle, and inject. That's the full technical complexity of it. Further detail on what the tirzepatide pen contains and how it's packaged covers the pen's physical format in more depth.

Step 2, Preparing for your injection correctly

Preparation is mostly about consistency. Picking the same rough time each week (many people anchor it to a weekend morning) makes the routine stick. The pen lives in the fridge between 2–8°C; check the Patient Information Leaflet for the exact room-temperature window, since that changes once the pen is out of the fridge and the leaflet carries the authoritative figure.

Before injecting, wash your hands. Clean the skin at your chosen site with an alcohol swab and let it dry completely, injecting through wet skin increases local irritation. Medical-grade alcohol swabs designed for this purpose are available separately if you need them. Attach a fresh needle each time; reusing a needle blunts the tip and raises infection risk.

The three licensed injection sites are the abdomen (at least a few centimetres from the navel), the front or outer thigh, and the upper arm. Rotate between sites and within sites week by week, the full injection technique guide explains how to map a rotation pattern that avoids the same spot twice in a row. Rotating matters more than most people realise; using one small patch repeatedly can cause the tissue underneath to harden, which affects absorption.

Step 3 (Injecting and what to expect at each dose stage

Press the pen firmly and steadily against the skin) no pinching needed for most adults, then press and hold the injection button until the click confirms the dose is complete. Hold for a further ten seconds before removing, to reduce leakage. The needle is covered automatically after use; place it directly into a sharps container rather than recapping, and dispose of the container via your local council's sharps scheme.

Treatment begins at 2.5 mg, a dose chosen to let the body adjust rather than to produce immediate weight loss. Your prescriber will review progress before any increase. The titration schedule (moving through 5 mg, 7.5 mg, 10 mg, 12.5 mg and up to 15 mg in steps) is set by the prescriber based on your tolerance and response. Nausea and digestive discomfort are most common in the days after a dose increase; they usually settle within one to two weeks. The Mounjaro injection overview covers what to do if side effects persist.

If you're weighing up what the treatment costs alongside how it works, the cost context page explains what legitimate private pricing typically includes. As the NHS tirzepatide medicines page notes, tirzepatide is a prescription-only medicine; the prescriber decides both the starting dose and when to move up.

Step 4, Ongoing use and what to bring to your clinical reviews

Once the initial adjustment period passes, most people settle into a straightforward weekly routine. The pen arrives in your fridge, you inject on your chosen day, and the clinical review before each repeat order checks that the dose is still appropriate and that any side effects are being managed well.

A few practical points that often get missed: if you travel, the pen can be kept at room temperature for a limited window, always check the leaflet rather than guessing. Never share a pen with anyone else. If a dose is missed, the tirzepatide injection guidance explains the timing rules, though the final word always sits with your prescriber and the PIL. Bring a note of any side effects, your current weight, and any other medicines you've started since your last review; that information shapes the prescriber's decision at each repeat.

Our clinical team reviews every consultation personally, a real prescriber reads your record, not software. Questions between orders go to our aftercare team, available seven days a week. If you're ready to start the process, the next step is a free consultation with our prescribers via our weight-loss treatments page.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions